Switzerland’s economic future is in the hands of pharmas

Image: Shutterstock

Under the threat of surcharge of 39% brandished by Donald Trump-from which they are currently exempt-the “pharmas” are invited to formulate concrete proposals to lower prices in the United States. Interpharma defends the freedom of the sector to set its prices abroad.

It is up to pharmaceutical companies to decide at what price they sell their medicines in the United States, spokesperson for the Pressharma Michèle Sierro spokesperson on Saturday. In the meantime, the organization asks Switzerland to reform its own price fixing system.

In the RTS Forum program, Sierro explained that in the United States, whose President Donald Trump asks the “pharmas” in particular to lower the prices of their medicines, these prices were set by the market. It is up to manufacturers to decide them. In Switzerland, on the other hand, prices are established by the State. A system described as “obsolete” by Interpharma.

Log until the end of September for the sector

“We are asking for a reform of this system (set by the State) because it is not suitable for innovative products.” Michèle Sierro said that the cost of developing a new drug was 2.5 billion, and that 90% of attempts were failures. “Novartis and Roche need enormous capital to be able to invest in research,” she said.

Swiss pharmaceutical exports are currently exempt from surcharge of 39% decided by Trump. But the latter would have given a delay until September 29 to the pharmas to make concrete proposals in order to lower their prices, failing which sanctions would be taken.

“We are in contact with the pharmas, and these contacts will be strengthened,” said Economy Minister Guy Parmelin at Forum.

ats

People suffering from Covid Long has long been looking for a cure for their evil. A new solution, inexpensive, is popular at the moment: nicotine patches.